Recombinant antibodies for the diagnosis and therapy of human disease

Current Opinion in Drug Discovery and Development

Volumn 2, Issue 2, 1999, Pages 110-117

  King, David J ^a   Adair, John R ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; AFELIMOMAB; ALEMTUZUMAB; ANTI LFA 1; BEC 2; CDP 771; CLENOLIXIMAB; EDRECOLOMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAK 195F; MEDI 500; MELANOMA VACCINE; MONOCLONAL ANTIBODY; ODULIMOMAB; OKT 3; PALIVIZUMAB; RECOMBINANT ANTIBODY; RHUMAB E25; RITUXIMAB; SEVIRUMAB; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLON CROHN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; GRAFT REJECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RHEUMATOID ARTHRITIS; SEPTIC SHOCK;

EID: 0032917730     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Persidis A: Biotechnology in 1998 and beyond. Nat Biotechnol (1998) 16:1378-1379.
2. Adair JR: Antibody engineering and expression. In: Biotechnology. A multi-volume comprehensive treatise, Volume 5a: Recombinant proteins, monoclonal antibodies and gene therapy, Mountain A, Ney U, Schomberg D (Eds), Wiley-VCH, Weinheim, FRG (1999) 219-244.
3. Dall'Acqua W, Carter P: Antibody engineering. Curr Opin Struct Biol (1998) 8:443-450.
4. Hudson PJ: Recombinant antibody fragments. Curr Opin Biotechnol (1998) 9:395-402.
5. Khazaeli MB, Conry RM, LoBuglio AF: Human immune response to monoclonal antibodies. J Immunother (1994) 15:42-52.
6. Kovarik J, Wolf P, Cisteme JM, Mourad G, Lebranchu Y, Lang P, Bourbigot B, Cantarovich D, Girault D, Gerbeau C, Schmidt AG, Soulillou JP: Disposition of basiliximab, an interleukin2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts. Transplantation (1997) 64:1701-1705.
7. Centocor warns of immune reaction with Remicade. Scrip (1998)2390:15.
8. King DJ (Ed): In: Applications and engineering of monoclonal antibodies. Taylor & Francis, London (1998).
9. HERZ monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996)14:737-744.
10. Stephens S, Emtage S, Vetteriein O, Chaplin L, Bebbington C, Nesbitt A, Sopwith M, Athwal D, Novak C, Bodmer M: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology (1995) 85:668-674.
11. Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith II JW, Clark JW, Dailey V, Del Vecchio S: Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Onco/(1990) 8:476-490.
12. Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR: Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience. Transplant Proc (1998) 30:1369-1370.
13. Rader C, Barbas III CF: Phage display of combinatorial antibody libraries. CurrOpin Biotechnol (1997) 8:503-508.
14. Vaughan TJ, Williams AJ, Pritchard K, Osboum JK, Pope AR, Eamshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS: Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol (1996) 14:309-314.
15. Brdggemann M, Taussig MJ: Production of human antibody repertoires in transgenic mice. Curr Opin Biotechnol (1997) 8:455-458.
16. Jakobovits A: The long awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice. Exp Opin Invest Drugs (1998) 7:607-614.
17. Vaughan TJ, Osboum JK, Tempest PR: Human antibodies by design. Nat Biotechnol (1998) 16:535-539.
18. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M: A subclass of tumor-inhibitory monoclonal antibodies to ErbB2/HER2 blocks crosstalk with growth factor receptors. Oncogene(1997) 14:2099-2109.
19. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized antipi 85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol (1998) 16:2659-2671.
20. McLaughlin P, Grillo-Lôpez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol (1998)16:2825-2833.
21. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. B/ood(1998) 92:1927-1932.
22. James N, Atherton P, Koletsky A, Tchekmedyian N, Cumow R: Phase II trial of the bispecific antibody MDX-H210 (antiHER2/neu x anti-CD64) combined with GM-CSF in patients with advanced prostate and renal cell carcinomas that express HER2/neu. Proc Am Soc Clin Oncol (1998) 17:436a, Abstract 461.
23. Carter P, Merchant AM: Engineering antibodies for imaging and therapy. CurrOpin Biotechnol (1997) 8:449-454.
24. Plückthun A, Pack P: New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 3:83-105.
25. Riethmüller G, Holz E, Schlimok G, Schmiege! W, Raab R, Höffken K, Gruber R, Funke l, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: sevenyear outcome of a multicenter randomized trial. J Clin Oncol (1998)16:1788-1794.
26. Yarranton G: Antibodies as carriers of drugs and radioisotopes. In: Antibody therapeutics, Harris WJ, Adair JR (Eds),. CRC Press Inc. Boca Raton, USA (1997) 53-72.
27. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, Fisher S, Regan D, Kroll S, Kaminski MS: Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med (1998) 39(8):21S27S.
28. Siegal JA: Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med (1998) 39(8):28S-33S.
29. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Lues TM, Grillo Lopez A, Chinn P, Vams C, Ning S, Fowler S, Deb N, Becker M, Marquez C, Levy R: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res (1996) 2:457-470.
30. Press OW, Shan D, Howell-Clark J, Eary J, Applebaum FR, Matthews D, King DJ, Haines AMR, Hamann P, Hinman L, Shochat D, Bernstein ID: Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res (1996)56:2123-2129.
31. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ: Phase 1/11 study of iodine 125-labelled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1996) 14:1787-1797.
32. Behr TM, Sgouros G, Vougioukas V, Memtsoudis S, Gratz S, Schmidberger H, Blumenthal RD, Goldenberg DM, Becker W: Therapeutic efficacy and dose-limiting toxicity of Augerelectron vs beta emitters in radioimmunotherapy with internalising antibodies: evaluation of '"!- vs "'l-labeled CO17-1A in a human colorectal cancer model. Int J Cancer (1998)76:738-748.
33. fxjorman TJ, Parker D, Smith FC, King DJ: Towards selective DNA targeting: synthesis of an antibody macrocycleiritercalator conjugate. J Chem Soc Chem Commun (1995):1879-1880.
34. /Begent RHJ, Verhaar MJ, Chester KA, Casey JL, Green AJ, .' Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, Hawkins RE, Hilson AJW, Robson L: Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med (1996)2:979-984. First clinical study with a single-chain Fv.
35. Sharkey RM, Blumenthal RD, Behr TM, Wong GY, Haywood L, Forman D, Griffiths GL, Goldenberg DM: Selection of radioimmunoconjugates for the therapy of wellestablished or micrometastatic colon carcinoma. Int J Cancer (1997) 72:477-485.
36. Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RHJ: Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Br J Cancer(1996) 74:1397-1405.
37. Zhu H, Baxter LT, Jain RK: Potential and limitations of radioimmunodetection and radioimmunotherapy with monoclonal antibodies. JNucl Med (1997) 38:731-741.
38. Berger MS, Hamann PR, Sopwith M: Antibody targeted chemotherapy. In: Biotechnology. A multi-volume comprehensive treatise, Volume Sa: Recombinant proteins, monoclonal antibodies and gene therapy, Mountain A, Ney U, Schomberg D (Eds). Wiley-VCH, Weinheim, FRG (1998) 355364.
39. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, Benz CC, Papahadjopoulos D: Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells In vitro. Biochemistry (1997) 36:66-75.
40. Multani PS, O'Day S, Nadler LM, Grossbard ML: Phase II clinical trial of bolus Infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell nonhodgkin's lymphoma. Clin Cancer Res (1998) 4:2599-2604.
41. Zewe M, Rybak SM, Dübel S, Coy JF, Welschof M, Newton DL, Little M: Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnobgy (1997) 3:127-136.
42. Bera TK, Pastan I: Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bioconjug Chem (1998) 9:736-743.
43. Pini A, Viti F, Santucci A, Camemolla B, Zardi L, Neri P, Neri D: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol C/?em(1998) 273:21769-21776.
44. Wu H, Beuerlein G, Nie Y, Smith H, Lee B, Hensler M, Huse WD, Watkins JD: Stepwise in vitro affinity maturation of Vitaxin, an ov3-specific humanized mAb. Proc Natl Acad Sci USA (1998) 95:6037-6042.
45. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by, antibody-directed targeting of tissue factor to tumor vasculature. Science (1997)275:547-550.
46. Seon BK, Malsuno F, Haruta Y, Kondo M, Barcos M: Longlasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res (1997)3:1031-1044.
47. Piccoli R, Oison KA, Vallée BL, Fett JW: Chimeric antiangiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. Proc Natl Acad Sci USA (1998) 95:4579-4583.
48. Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumours by anti-vascular endothelial growth factor neutralizing antibody. Cancer Res (1996) 56:4032-4039.
49. Klivenyi G, Schuhmacher J, Patzelt E, Hauser H, Matys R, Moock M, Regiert T, Maier-Borst W: Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med (1998) 39:1769-1776.
50. Breitz HB, Fisher DR, Wessels BW: Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med (1998) 39:1746-1751.
51. Bagshawe K: Developments with targeted enzymes. Tumor Targeting (1998) 3:21 -24.
52. Martin J, Stribbling SM, Poon GK, Begent RHJ, Napier M, Sharma SK, Springer CJ: Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother Pharmacol (1997) 40:189-201.
53. Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS: The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. BrJ Rheumatol (1995)34:334-342.
54. Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME, Yang M, Bourell JH, Shepard HM, Henner D: High level Escherichia coli expression and production of a bivalent humanized antibody fragment Biotechnology (1992) 10:163-167.
55. Horn U, Strittmatter W, Krebber A, Knüpfer U, Kujau M, Wenderoth R, Müller K, Matzku S, Plückthun A, Riesenberg D: High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell density fermentation under non-limited growth conditions. Appl Microbiol Biotechnol (1996) 46:524-532.
56. Kipriyanov SM, Moldenhauer G, Martin AC, Kupriyanova OA, Little M: Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng (1997) 10:445-453.
57. Knappik A, Plückthun A: Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng (1995) 8:81-89.
58. Nieba L, Honegger A, Krebber C, Piückthun A: Disrupting the Hydrophobie patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng (1997) 10:435-444.
59. Bothmann H, Piückthun A: Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat Biotechnol (1998) 16:376-380.
60. Martineau P, Jones P, Winter G: Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol B/o/(1998) 280:117-127.
61. FitzGerald K, Holliger P, Winter G: Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng (1997) 10:1221-1225.
62. Shusta EV, Raines RT, Piückthun A, Wittrup KD: Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nat Biotechnol (1998) 16:773-777.
63. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES: Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol (1997) 15:637-640.
64. Pedley RB, Boden JA, Boden R, Begent RHJ, Turner A, Haines AM, King DJ: The potential for enhanced tumour localisation by poly(ethylene glycol) modification of antiCEA antibody. Br JCance/-(1994) 70:1126-1130.
65. Pen J: Comparison of host systems for the production of recombinant proteins. In: Transgenic plants: a production system for industrial and pharmaceutical proteins. Owen MRL, Pen J (Eds). John Wiley and Sons, London (1996) 149-167.
66. DiTuilio P, Ebert K, Pollock D, Harvey M, Williams J: Highlevel production of of human monoclonal antibody in the milk of transgenic mice and a transgenic goat. IBC conference on Antibody Engineering, La Jolla, CA, USA (1995), conference proceedings.
67. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH: Viable offspring derived from fetal and adult mammalian cells. Nature (1997) 385:810-813.
68. Schnieke AE, Kind AJ, Ritchie WA, Mycock K, Scott AR, Ritchie M, Wilmut I, Colman A, Campbell KH: Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science (1997) 278:2130-2133.
69. Ma JKC, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, Hein MB, Lehner T: Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. A/af Med(1998) 4:601-606.
70. Franken E. Teuschel U, Hain R: Recombinant proteins from transgenic plants. Curr Opin Biotechnol (1997) 8:411-416.